Compare BANF & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANF | CRNX |
|---|---|---|
| Founded | 1984 | 2008 |
| Country | United States | United States |
| Employees | 2135 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.9B |
| IPO Year | N/A | 2018 |
| Metric | BANF | CRNX |
|---|---|---|
| Price | $113.66 | $39.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $124.00 | $76.63 |
| AVG Volume (30 Days) | 126.4K | ★ 1.1M |
| Earning Date | 04-17-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,039,000.00 |
| Revenue This Year | $6.10 | $720.10 |
| Revenue Next Year | $3.92 | $184.67 |
| P/E Ratio | $16.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $101.22 | $25.83 |
| 52 Week High | $138.15 | $57.99 |
| Indicator | BANF | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 59.69 | 55.55 |
| Support Level | $107.26 | $39.35 |
| Resistance Level | $115.58 | $45.32 |
| Average True Range (ATR) | 2.81 | 1.61 |
| MACD | 1.00 | 0.85 |
| Stochastic Oscillator | 71.60 | 87.76 |
BancFirst Corp is engaged in providing banking services. The company's business unit includes BancFirst metropolitan banks, BancFirst community banks, Pegasus Bank, Worthington, other financial services and executive, operations and support. BancFirst metropolitan banks, BancFirst community banks, Pegasus and Worthington offer traditional banking products such as commercial and retail lending and a full line of deposit accounts. Other financial services are specialty product business units including guaranteed small business lending, residential mortgage lending, trust services, securities brokerage, electronic banking, and insurance.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.